NCT02567435 2026-04-13
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Seagen Inc.
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
University of Oxford